Invivogen
Menu

InvivoGen Reviews

Read the Review
Read the Review

Immune Checkpoint Blockade: InestimAble Advances

Over the last decade, the understanding of key steps in the regulation of T cell responses has led to the groundbreaking development of immune checkpoint blocking monoclonal antibodies (mAbs) to fight cancer. The first FDA-approved mAbs have provided unprecedented remissions in melanoma and non-small cell lung cancer, although with considerable variation in response rates (10% to 90%) and significant toxicity1,2. This revolution in cancer therapy is now the basis for new IC-based curative strategies.

Previous issues

Pages

Customer Service
& Technical Support
Contact us
Shopping cart is empty